Comparative Pharmacology
Head-to-head clinical analysis: CRYSELLE versus NORTREL 7 7 7.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CRYSELLE versus NORTREL 7 7 7.
CRYSELLE vs NORTREL 7/7/7
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cryselle is a combination oral contraceptive containing ethinyl estradiol and norgestrel. It inhibits ovulation by suppressing gonadotropin release, primarily through estrogenic and progestogenic effects on the hypothalamic-pituitary axis. It also increases cervical mucus viscosity and alters endometrial structure, impeding sperm penetration and implantation.
Combination estrogen-progestin oral contraceptive. Suppresses gonadotropin release, inhibiting ovulation. Increases cervical mucus viscosity and alters endometrial receptivity.
One tablet (0.3 mg norgestrel/0.03 mg ethinyl estradiol) orally once daily at the same time each day for 21 consecutive days, followed by 7 days of placebo.
One tablet orally once daily, taken at the same time each day. Each tablet contains norethindrone 0.5 mg/ethinyl estradiol 35 mcg for days 1-7, norethindrone 0.75 mg/ethinyl estradiol 35 mcg for days 8-14, and norethindrone 1 mg/ethinyl estradiol 35 mcg for days 15-21, followed by 7 placebo tablets.
None Documented
None Documented
Terminal elimination half-life approximately 24 hours (range 16-36 h), with clinical significance for once-daily dosing.
Norelgestromin terminal half-life is approximately 28 hours; ethinyl estradiol terminal half-life is approximately 17 hours. The extended half-life supports once-weekly dosing.
Renal (50% as metabolites, 20% unchanged), fecal (30%), with enterohepatic recirculation.
Renal excretion of metabolites (primarily ethinyl estradiol and norelgestromin conjugates) accounts for approximately 50% of elimination; fecal/biliary excretion accounts for the remainder (about 35-40% fecal, 10-15% biliary).
Category C
Category C
Oral Contraceptive
Oral Contraceptive